ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
24.81
+1.38 (5.89%)
Mar 9, 2026, 4:00 PM EDT - Market closed
ArriVent BioPharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -166.31 | -80.49 | -69.33 | -36.91 | -68.81 |
| Asset Writedown & Restructuring Costs | - | - | - | - | 57.21 |
| Stock-Based Compensation | 12.52 | 3.21 | 0.9 | 0.42 | 0.07 |
| Other Operating Activities | -3.03 | - | - | - | - |
| Change in Accounts Payable | 2.14 | -0.75 | 1.38 | 2.8 | 0.39 |
| Change in Other Net Operating Assets | -5.92 | 7.82 | 11.22 | -9.95 | -5.65 |
| Operating Cash Flow | -160.59 | -70.21 | -55.84 | -43.63 | -16.78 |
| Sale (Purchase) of Intangibles | - | - | - | - | -53.33 |
| Investment in Securities | -71.23 | -192.47 | - | - | - |
| Investing Cash Flow | -71.23 | -192.47 | - | - | -53.33 |
| Total Debt Issued | - | - | - | - | 0.27 |
| Total Debt Repaid | - | - | - | - | -0.27 |
| Issuance of Common Stock | 203.13 | 186.58 | 0.35 | 0.02 | 0 |
| Other Financing Activities | -0.07 | - | -2.41 | - | - |
| Financing Cash Flow | 203.06 | 186.58 | 42.86 | 169.72 | 119.82 |
| Net Cash Flow | -28.75 | -76.1 | -12.98 | 126.09 | 49.71 |
| Levered Free Cash Flow | -101.58 | -48.64 | -32.8 | -29.81 | - |
| Unlevered Free Cash Flow | -101.58 | -48.64 | -32.8 | -29.81 | - |
| Change in Working Capital | -3.77 | 7.07 | 12.6 | -7.15 | -5.25 |
Source: S&P Capital IQ. Standard template.
Financial Sources.